CD8A and non-small cell lung carcinoma: found that CD8+ T cells from NSCLC and melanoma patients with musculoskeletal irAEs, when treated in vitro with tofacitinib, continued to secrete cytokines and display immune‐effector cell surface markers, inhibiting lung cancer progression.